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Background. The hepatitis C virus (HCV) epidemic is evolving rapidly in patients infected with human immu-
nodeﬁciency virus (HIV). We aimed to describe changes in treatment uptake and outcomes of incident HCV infec-
tions before and after 2006, the time-point at which major changes in HCV epidemic became apparent.
Methods. We included all adults with an incident HCV infection before June 2012 in the Swiss HIV Cohort
Study, a prospective nationwide representative cohort of individuals infected with HIV. We assessed the following
outcomes by time period: the proportion of patients starting an HCV therapy, the proportion of treated patients
achieving a sustained virological response (SVR), and the proportion of patients with persistent HCV infection dur-
ing follow-up.
Results. Of 193 patients with an HCV seroconversion, 106 were diagnosed before and 87 after January 2006. The
proportion of men who have sex with men increased from 24% before to 85% after 2006 (P < .001). Hepatitis C virus
treatment uptake increased from 33% before 2006 to 77% after 2006 (P < .001). Treatment was started during early
infection in 22% of patients before and 91% after 2006 (P < .001). An SVR was achieved in 78% and 29% (P = .01) of
patients treated during early and chronic HCV infection. The probability of having a detectable viral load 5 years
after diagnosis was 0.67 (95% conﬁdence interval [CI], 0.58–0.77) in the group diagnosed before 2006 and 0.24 (95%
CI, 0.16–0.35) in the other group (P < .001).
Conclusions. In recent years, increased uptake and earlier initiation of HCV therapy among patients with inci-
dent infections signiﬁcantly reduced the proportion of patients with replicating HCV.
Keywords. acute HCV; treatment outcomes; treatment uptake.
We recently observed dramatic changes in the hepatitis
C virus (HCV) infection epidemic in the Swiss HIV
Cohort Study (SHCS), including an 18-fold incidence
increase in men who have sex with men (MSM) [1].
Hepatitis C virus infection is a major cause of morbidity
and mortality in patients infected with human immu-
nodeﬁciency virus (HIV) and, if left untreated, often
leads to liver cirrhosis and hepatocellular carcinoma
[2]. The long-term trends in treatment uptake and out-
comes of incident HCV infections are largely unknown.
Because spontaneous clearance of the virus is only seen
in a minority of patients [3, 4], most individuals infect-
ed with HIV with an acute HCV infection would beneﬁt
from early diagnosis and treatment. Sustained virol-
ogical response (SVR) rates of 60%–80% have been ob-
served in selected groups of patients infected with HIV
if antiviral therapy with pegylated interferon (Peg-IFN)
and ribavirin (RBV) was initiated within 1 year after
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HCV diagnosis [5, 6]. However, no clinical trial comparing the
success of early versus deferred HCV therapy in patients infect-
ed with HIV have been performed to date, and previous obser-
vational studies were limited by small patient numbers or
restricted to outbreaks in large urban centers [7–9].
Early diagnosis of HCV infections and uptake of treatment
have generally been suboptimal in most HIV clinics [10, 11].
This implies that despite the availability of effective HCV ther-
apy, the overall burden of liver disease due to HCV in patients
infected with HIV remains very high and that HIV/HCV-
coinfected patients can transmit HCV for many years. Thus,
it is now evident that a relevant impact on global HCV trans-
mission and HCV-related mortality will only be achieved if up-
take of treatment is massively increased [12, 13]. In recent years,
the concept of a cascade or pyramid of care for HIV infection
has attracted much attention from public health authorities, in
both low- and high-income countries, and helped evaluate and
improve the progress of HIV care [14, 15]. The evaluation of
HCV care and treatment programs with a similar approach
would help identify the most important gaps in HCV manage-
ment and inform future strategies and policies regarding HCV
management.
We studied the natural history and treatment uptake of all in-
cident HCV infections between 1991 and 2012 in a nationwide
HIV cohort and compared HCV treatment outcomes between
patients who experienced a seroconversion before and after the
ﬁrst description of the surging epidemic among MSM in 2005
[16–18].We also intended to show the impact of early treatment
on the pyramid of HCV care and the proportion of the popu-
lation with a detectable viral load.
METHODS
Swiss HIV Cohort Study
The SHCS (www.shcs.ch) is a prospective nationwide cohort
study with ongoing enrollment of adults infected with HIV in
Switzerland since 1988. It covers approximately 50% of the cu-
mulative number of HIV infections declared to the Swiss public
health authorities and 75% of patients receiving antiretroviral
therapy (ART) in Switzerland [19]. Detailed information on de-
mographics, mode of HIV acquisition, risk behavior, clinical
events, coinfections, and treatment is collected using a standard
protocol at registration and then at 6-month intervals. All par-
ticipants are screened for HCV infection at study entry. Since
1998, HCV serology is repeated at least every 24 months in
all patients. Local ethical committees of all participating study
sites have approved the study, and written consent has been ob-
tained from all participants.
Inclusion Criteria and Deﬁnitions
All patients with a documented HCV seroconversion before
June 2012 and a follow-up of at least 6 months thereafter
were considered. Patients who had a single positive anti-HCV
antibody test but a negative immunoblot, no positive RNAmea-
surement, and negative follow-up anti-HCV antibody tests were
classiﬁed as false-positives and excluded from the analyses. Nat-
ural history and treatment outcomes were deﬁned as follows:
spontaneous clearance, single negative HCV viral load after a
conﬁrmed incident infection without any HCV treatment;
SVR, undetectable HCV RNA 6 months after completion of
HCV treatment; persistent infection, detectable HCV RNA at
least 1 year after diagnosis of incident HCV infection; rein-
fection, either an HCV genotype switch after a ﬁrst infection
or a newly detectable HCV viral load after spontaneous clear-
ance or treatment-induced SVR; early infection, within 12
months of HCV diagnosis. The latter deﬁnition takes into ac-
count previous studies that demonstrated that high SVR are
achieved if HCV treatment is started within the ﬁrst year after
seroconversion [6].
Data Collection
In addition to the individual data collected routinely within the
framework of the SHCS, we performed medical chart reviews to
collect detailed information on HCV diagnosis, natural history,
and treatment using standardized case report forms. The rea-
sons (from the provider’s perspective) for not starting HCV
treatment, as well as symptoms and side-effects leading to an
HCV treatment interruption or dosage adaptation, were also re-
trieved. Furthermore, all additional HCV viral load and trans-
aminase measurements were included. IL28B genotypes were
determined using TaqMan Genotyping Master Mix (Life Tech-
nologies, Carlsbad, CA), as described previously [20].
Statistical Analyses
Baseline demographic and clinical characteristics at time of
HCV seroconversion were described using absolute numbers
and proportions, or medians and interquartile ranges, and
were compared between time periods (before and after January
1, 2006) using the χ2, Fisher’s exact, or Mann–Whitney U test,
where appropriate. January 2006 was chosen because by then
the ﬁrst reports on the possible sexual transmission of HCV
in MSM in Europe had been published, and the awareness of
this epidemiological trend among physicians and public health
authorities was increasing in Switzerland [16–18, 21]. Similarly,
natural history as well as treatment uptake were compared be-
tween time periods. Hepatitis C virus therapy outcomes were
compared between patients who received treatment during the
ﬁrst year after seroconversion (“early infection”) and the others.
Kaplan–Meier analyses were used to compare the probability
of HCV suppression over time between patients diagnosed
before and after 2006. For the latter analysis, follow-up was cen-
sored at ﬁrst HCV suppression, death, or drop out, whichever
happened ﬁrst. This analysis included only follow-up time after
2002 because HCV viral load measurements were infrequent
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before that year. All statistical analyses were performed using
Stata 12.0 (Stata Corp, College Station, TX) and R version 3.0.2
with the survival and ggplot2 (http://cran.r-project.org/web/




Of 237 patients with a newly positive screening HCV serology,
34 were considered false-positives and 203 were HCV serocon-
versions. Ten additional patients were excluded due to insufﬁ-
cient information. The baseline demographic and clinical
characteristics of the 193 patients included in our analyses are
shown in Table 1. One hundred six patients were diagnosed
with an incident HCV infection before 2006, and 87 patients
were diagnosed after January 2006. Patients with incident in-
fections diagnosed from 2006 onwards were more likely to be
MSM (85% vs 24%, P < .001) and to be on ART (94% vs 76%,
P < .001) compared with individuals diagnosed before 2006.
Of 64 HCV infections in people who inject drugs (PWID),
only 4 were diagnosed after 2006. Patients with acute HCV in-
fections after 2006 had a higher sexual risk behavior than those
diagnosed in earlier years: the proportion with inconsistent
condom use (78% vs 33%, P < .001), occasional sexual partners
(84% vs 26%, P < .001), and history of syphilis (45% vs 7%,
P < .001) was higher after 2006. Hepatitis C virus genotype 1
was more frequent after 2006 (57% vs 49%), whereas the pro-
portion of genotype 3 infections decreased after January 2006
(19% vs 25% before 2006). The proportion of genotype 4 in-
fections remained stable over time, and only 3 patients had a
genotype 2 infection.
Natural Course and Treatment Uptake
A spontaneous clearance was observed in 48 cases (32% of those
not treated during acute infection) (Figure 1). Treatment uptake
changed over time, with a major increase from 2006 onwards
(Supplementary Figure 1). Overall, 49 patients (25%) were treat-
ed during the early phase of HCV infection, and 96 patients
(50%) progressed to chronic HCV infection. Hepatitis C virus
treatment uptake increased from 33% before 2006 to 77%
after 2006 (P < .001). Among those treated, only 22% (6 pa-
tients, including 3 MSM) started treatment during early infec-
tion before 2006, compared with 91% (43 patients, including 40
MSM) after 2006 (P < .001). Among patients without spontane-
ous clearance, HCV treatment uptake was higher in MSM com-
pared with PWID before (21% vs 0%) and after 2006 (71% vs
50%). Of 96 patients with persistent infection, only 25 (26%)
were treated during follow-up. The most frequent reasons for
patients diagnosed before 2006 not to be treated were “persis-
tent alcohol or drug abuse” (25%), followed by “patient’s refusal”
(21%). After 2006, “other psychiatric comorbidities” and “wait-
ing for new direct-acting antivirals (DAAs)” became additional
important reason for not starting therapy (20% each). Past non-
injecting drug use was not a barrier for early HCV therapy: for
patients diagnosed after 2006, it was reported in 56% of patients
with early HCV therapy, compared with 44% in those with
spontaneous clearance and 47% in patients who were not treat-
ed for HCV. Overall, 11 patients experienced an HCV reinfec-
tion, including 9 MSM and 2 PWID. Of these, 6 patients (all
MSM) had a reinfection after a treatment-induced SVR, and 5
patients had a reinfection after spontaneous clearance. In total,
23 (12%) patients died during follow-up.
Treatment Outcomes
Seventy of 74 treated patients had an available treatment out-
come at time of database closure and were included in this anal-
ysis. All patients were treated with Peg-IFN and RBV, but DAAs
were not used. An SVR was achieved in 78% and 29% (P = .01)
of patients treated during early and chronic HCV infection,
Table 1. Characteristics of Patients With Incident HCV Infection






or After Jan 2006
(n = 87) P Value
Female sex (%) 29 (27.4) 4 (4.6) <.001
Median age in years
(IQR)
31 (28–39) 34 (30–40) .03
Median CD4 in
cells/μL (IQR)
363 (220–613) 507 (359–675) .001
On ART (%) 80 (75.5) 82 (94.3) <.001
Suppressed HIV
VL (%)
58 (54.7) 69 (79.3) <.001
Occasional sexual
partners (%)
27 (25.5) 73 (83.9) <.001
Inconsistent condom
use (%)
35 (33.0) 68 (78.2) <.001




MSM 25 (23.6) 74 (85.1)
PWID 60 (56.6) 4 (4.6)
HET 15 (14.2) 7 (8.1)




1 34 (49.3) 38 (56.7)
2 2 (2.9) 1 (1.5)
3 17 (24.6) 13 (19.4)
4 16 (23.2) 15 (22.4)
Abbreviations: ART, antiretroviral therapy; HCV, hepatitis C infection; HET,
heterosexual; HIV, human immunodeficiency virus; IQR, interquartile range;
MSM, men who have sex with men; PWID, people who inject drugs; VL,
viral load.
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respectively (Figure 2). In patients treated during early HCV in-
fection, SVR was high irrespective of the IL28B genotype (19 of
25 [76%] in C/C and 16 of 20 [80%] in non-C/C genotypes),
whereas SVR differed between IL28B genotypes in those treated
during chronic infection (3 of 6 [50%] vs 4 of 16 [25%] in CC
and non-CC, respectively). Among patients treated during early
infection, there was no signiﬁcant difference in SVR rates between
genotypes: genotype 1, 17 of 26 (65%); genotype 2, 2 of 2
(100%); genotype 3, 8 of 8 (100%); genotype 4, 7 of 8 (88%)
(P = .14). Of 46 patients treated during the early phase of infec-
tion, only 9 (20%) experienced a relapse or a nonresponse,
whereas this proportion reached 50% in those treated during
the chronic phase of infection.
Pyramid of Care and Population Effect
Before 2006, only 33% of patients without spontaneous clear-
ance of HCV were treated for their HCV infection, and 12% pa-
tients achieved a treatment-induced SVR overall (Figure 3). If
the 23 patients with a spontaneous clearance were added to
this estimation, the overall proportion with a resolved infection
in this time period was 31%. In comparison, after 2006, 77% of
patients without a spontaneous clearance were treated, and 53%
achieved a SVR. Adding the 25 spontaneous clearances during
this period resulted in an overall proportion of individuals with
a resolved infection reaching 67%. Figure 4A shows the Kaplan–
Meier curves of HCV viral load detectability by time period,
over a total of 706 person-years of follow-up. The 5-year
Figure 1. Natural course of hepatitis C virus (HCV) infection and treatment uptake in HIV-infected patients with incident HCV infection before (A) and
after (B) January 2006.
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probability of having a detectable viral load was 0.67 (95% con-
ﬁdence interval [CI], 0.58–0.77) in the group diagnosed before
2006 and 0.24 (95% CI, 0.16–0.35) in the other group (log rank
test; P < .001). The overall proportion of patients with a detect-
able HCV viral load in the cohort decreased over time, from
0.95 (95% CI, 0.84–0.98) in 2002 to 0.70 (95% CI, 0.61–0.77)
in 2012 (Figure 4B). The full picture of individual HCV viral
loads over time in the whole cohort is shown in Supplementary
Figure 2.
DISCUSSION
In this nationwide cohort of patients infected with HIV with an
incident HCV infection, overall treatment uptake during early in-
fection was low, but it improved after 2006, the year after the dis-
semination of the ﬁrst reports on sexual transmission of HCV in
HIV-infected MSM. After 2006, 85% of acute HCV infections
were observed in MSM. These patients were much more likely
to be treated during early stages of infection compared with pa-
tients diagnosed before 2006, who were mainly PWID. In HCV
infections treated during the ﬁrst year after diagnosis, an SVR was
reached in 78% of cases, compared with only 29% in those treated
during chronic infection. Improved treatment uptake after 2006
led to a continuous decrease in the overall proportion of patients
with a detectable HCV viral load.
Trends in the epidemiology of HCV infections among pa-
tients infected with HIV are rapidly evolving. This nationwide
observational study underlines these changes, because the pro-
portion of MSM in acute HCV infections increased from 24%
before 2006 to 85% after 2006. We previously showed that this
increase was associated with high-risk sexual behavior, includ-
ing a history of past syphilis infection [1]. The present study
highlights the dramatic change in sociobehavioral trends of
the population affected by the HCV epidemic: from mainly
PWID before 2006 to MSM with stable HIV infections under
ART but poor condom use and frequent occasional partners
after January 2006.
Figure 2. Hepatitis C virus (HCV) treatment outcomes by stage of infec-
tion. Abbreviation: SVR, sustained virological response.
Figure 3. Pyramid of care for incident hepatitis C virus (HCV) infections in the Swiss HIV Cohort Study. (Patients with spontaneous clearance of HCV have
been excluded from this analysis.) Abbreviation: SVR, sustained virological response.
Acute HCV in the Swiss HIV Cohort Study • OFID • 5
Hepatitis C virus therapy outcomes with Peg-IFN and RBV
are improved when treatment is started during the early
phase of infection, as shown in large trials of HCV-monoin-
fected patients [22] and in several observational studies in co-
horts of patients infected with HIV [7, 8]. Our results conﬁrm
these ﬁndings, because 78% of the patients treated within the
ﬁrst year after HCV seroconversion achieved an SVR. This es-
timate was slightly higher than what was observed in a multi-
center European cohort study (62% SVR) [7]. In accordance
with the results from a large HIV cohort collaboration [23],
IL28B genotype did not have an impact on acute HCV treat-
ment outcomes in the SHCS.
Early HCV diagnosis and treatment uptake are 2 of the most
important bottlenecks towards the eradication of HCV infec-
tion [12, 13, 24]. Treatment uptake for acute and chronic
HCV infections has been consistently poor in most settings.
In a single center of the SHCS, only 8% of the patients chron-
ically infected started treatment with Peg-IFN and RBV by 2005
[10]. In the present study, we showed that before 2006, only a
minority of patients with an acute HCV infection was treated
accordingly. However, we observed a dramatic improvement
in treatment uptake after 2006: three quarters of acute HCV
infections were treated, including a large majority at an early
stage of infection, leading to a 2-fold increase in the overall pro-
portion of patients with a resolved infection in recent years. The
reports on the high cure rates that can be achieved if treatment is
started during acute infection were the rationale for starting
treatment before chronic HCV infection was established [25].
However, there are several additional reasons for this major in-
crease in treatment uptake: the most obvious one is the recent
changes in the characteristics of the populations infected with
an acute HCV. Treating MSM under stable ART and living in
good socioeconomic situations is often seen as being easier to
implement compared with the management of PWID in unsta-
ble conditions. This is in part reﬂected by the reasons for failing
to initiate HCV therapy in our study; as expected, these reasons
changed over time, mainly due to the comorbidities of the risk
population. Continuous substance abuse, an important issue in
assessing treatment eligibility in PWID, was replaced by other
psychiatric comorbidities in the most frequent reason for not
starting HCV therapy as an increasing number of noninjecting
MSM became infected. This underlines the need for the ongo-
ing optimal appraisal of psychiatric comorbidities in all HIV/
HCV-coinfected patients and gives rise to the hope that this
barrier will be less important in the context of HCV treatment
with new DAAs. However, several reports demonstrated that
HCV therapy is feasible despite ongoing substance abuse and,
in light of its individual and public health beneﬁts, should not
be withheld in patients willing to initiate anti-HCV therapy
[26]. Unlike in MSM, none of the PWID in our study had a re-
infection after treatment-induced clearance, which supports ev-
idence from other settings [27] and further underscores the
beneﬁt of HCV therapy in this population. Another explanation
for the increase in HCV treatment uptake may be the improve-
ment of the awareness of physicians regarding the diagnosis and
treatment of acute HCV infection since the description of the
ﬁrst HCV epidemics in MSM.
This study is the ﬁrst one to describe national long-term
trends in acute HCV treatment uptake and efﬁcacy among pa-
tients infected with HIV. It relies on detailed data from routine
monitoring and review of the medical charts of all patients, in-
cluding information on follow-up virological assessments and
reasons for not receiving HCV treatment. However, a substan-
tial number of patients had to be excluded because of possible
false-positive HCV serology results, which could not be con-
ﬁrmed by RNA measurements or immunoblot. This might
have led to the exclusion of patients with rapid spontaneous
HCV clearance and negative HCV follow-up serology and, as
a consequence, to an underestimation of the number of acute
HCV infections. Reinfections were identiﬁed using the SHCS
database complemented by review of patient charts including
transaminase levels and HCV RNA measurements. However,
we cannot exclude that some reinfections were not recognized
if transaminase levels had normalized before the next follow-up
Figure 4. Impact of treatment uptake on cumulative probability of hav-
ing a detectable hepatitis C virus (HCV) viral load (A) and on the proportion
in patients with incident HCV infections (B)
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visits, which are typically performed every 3 months. In contrast,
patients with ﬂuctuating HCV viral loads after infection who
ultimately progressed to chronic infection could have been mis-
classiﬁed as reinfected, which could have led to an overestima-
tion of the rate of reinfections. Furthermore, the reason for not
receiving any HCV therapy was not found in approximately one
third of the patients with a chronic, untreated HCV infection.
In analogy to the reduction of acquired immune deﬁciency
syndrome-related mortality in the context of the rapid scale
up of ART, a signiﬁcant impact on HCV-related mortality
will only be achieved with a massive improvement in the diag-
nosis and treatment uptake of HCV infection. In the HIV ﬁeld,
the continuous assessment of the cascade of care, including
HIV diagnosis, ART coverage, and efﬁcacy, has allowed the
adaption and improvement of public health policies and strat-
egies. Likewise, it is of primary importance to evaluate the pyr-
amid of care in terms of HCV infection management and
compare results across cohorts, settings, and countries. Our
study is the ﬁrst one to describe such a pyramid of care for in-
cident HCV infections in a nationwide cohort of individuals in-
fected with HIV. In future work, the proportion of patients with
an undetectable HCV viral load should be used as an important
measure of HCV treatment success, in analogy to the propor-
tion of patients with an undetectable HIV viral load in HIV
programs.
CONCLUSION
In the context of the increasing burden of liver-related morbid-
ity and mortality in HIV-infected individuals, the improvement
of HCV treatment uptake is of high priority. In the SHCS, HCV
treatment uptake during the early phase of HCV infection im-
proved over the years, leading to a 2-fold increase in the propor-
tion of patients with a resolved HCV infection in the cohort.
Even though most recent infections were diagnosed in MSM
with stable HIV infections, there remained important barriers
for treatment initiation including the presence of psychiatric co-
morbidities. The increasing availability of new IFN-free combi-
nations will reduce the impact of these treatment barriers.
Nevertheless, it is necessary to continue the efforts in terms
of early diagnosis and treatment uptake if HCV-related compli-
cations are to be reduced. Eradicating HCV infection dramati-
cally reduces the risk of liver-related death in patients infected
with HIV [28] and prevents further HCV transmissions. As we
demonstrate here, improvements in treatment uptake and efﬁ-
cacy substantially reduce the burden of replicating hepatitis C
among patients with incident HCV infections. Our study dem-
onstrates that frequent screening in clinical routine settings,
early diagnoses, and treatment of HCV infections in persons
with continued risk of infection are highly efﬁcient interven-
tions to reduce the burden of HCV disease at both the individ-
ual and the population level.
Supplementary Material
Supplementary material is available online atOpen Forum Infectious Diseases
(http://OpenForumInfectiousDiseases.oxfordjournals.org/).
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